Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A clinical association has been reported between type 1 Gaucher's disease, which is caused by a glucocerebrosidase deficiency owing to mutations in the glucocerebrosidase gene (GBA), and parkinsonism. We examined whether mutations in the GBA gene are relevant to idiopathic Parkinson's disease. METHODS: A clinic-based case series of 99 Ashkenazi patients with idiopathic Parkinson's disease, 74 Ashkenazi patients with Alzheimer's disease, and 1543 healthy Ashkenazi Jews who underwent testing to identify heterozygosity for certain recessive diseases were screened for the six GBA mutations (N370S, L444P, 84GG, IVS+1, V394L, and R496H) that are most common among Ashkenazi Jews. RESULTS: Thirty-one patients with Parkinson's disease (31.3 percent; 95 percent confidence interval, 22.2 to 40.4 percent) had one or two mutant GBA alleles: 23 were heterozygous for N370S, 4 were heterozygous for 84GG, 3 were homozygous for N370S, and 1 was heterozygous for R496H. Among the 74 patients with Alzheimer's disease, 3 were identified as carriers of Gaucher's disease (4.1 percent; 95 percent confidence interval, 0.0 to 8.5 percent): 2 were heterozygous for N370S, and 1 was heterozygous for 84GG. Ninety-five carriers of Gaucher's disease were identified among the 1543 control subjects (6.2 percent; 95 percent confidence interval, 5.0 to 7.4 percent): 92 were heterozygous for N370S, and 3 were heterozygous for 84GG. Patients with Parkinson's disease had significantly greater odds of being carriers of Gaucher's disease than did patients with Alzheimer's disease (odds ratio, 10.8; 95 percent confidence interval, 3.0 to 46.6; P<0.001) or control subjects (odds ratio, 7.0; 95 percent confidence interval, 4.2 to 11.4; P<0.001). Among the patients with Parkinson's disease, patients who were carriers of Gaucher's disease were younger than those who were not carriers (mean [+/-SD] age at onset, 60.0+/-14.2 years vs. 64.2+/-11.7 years; P=0.04). CONCLUSIONS: Our results suggest that heterozygosity for a GBA mutation may predispose Ashkenazi Jews to Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is a center for cellular signaling and signal integration, has responsibilities in trafficking cargo, and functionally interacts with other organelles.1,9”
From The lysosome and proteostatic stress at the intersection of pediatric neurological disorders and adult neurodegenerative diseases (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009).”
From Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples (2010) · cites this paper as Aharon-Peretz et al. 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Unified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,187
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Research works printed but not linked: 1
- 10.1002/(sici)1098-1004(1998)12:4<240::aid-humu4>3.0.co;2-j · doi:10.1002/(sici)1098-1004(1998)12:4<240::aid-humu4>3.0.co;2-j
Cited by
Items 401–500 of 608
Genome-wide Linkage Screen in Familial Parkinson Disease Identifies Loci on Chromosomes 3 and 18
Gao, X., Martin, E. R., Liu, Y., Mayhew, G. M., Vance, J. M., & Scott, W. K. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.03.005 · Cited by 13
Clinical Overview and Phenomenology of Movement Disorders
Fahn, S., Jankovic, J. J., Hallett, M., & Jenner, P. G. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.50004-8 · Cited by 15
Behavioral Phenotyping in a Murine Model of GBA1-Associated Parkinson Disease
Do, J., Perez, G., Berhe, B. A., Tayebi, N., & Sidransky, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136826 · Cited by 12
Senkevich, K. A., Miliukhina, I. V., Beletskaia, M., Gracheva, E., Kudrevatykh, A., Nikolaev, M. A., Emelyanov, A., Kopytova, A. E., Timofeeva, A., Yakimovskii, А. F., et al. (2017) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro201711710181-86 · Cited by 12
Movement and mood disorder in two brothers with Gaucher disease
Raja, M., Azzoni, A. B. M., Giona, F., Regis, S., Grossi, S., Filocamo, M., & Sidransky, E. (2007) · Clinical Genetics · doi:10.1111/j.1399-0004.2007.00863.x · Cited by 12
Lewthwaite, A. J., & Nicholl, D. J. (2005) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-005-0064-6 · Cited by 13
“Furthermore Aharon-Peretz et al. [ 92 ] described 99 Ashkenazi Jews with idiopathic PD of whom 31 had one or two mutant GBA alleles.”
BackgroundHou, W. C., Massey, L. A., Rhoades, D. J., Wu, Y., Ren, W., Frank, C., Overkleeft, H. S., & Kelly, J. W. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2320257121 · Cited by 11
Blauwendraat, C., Noyce, A. J., Mata, I. F., Screven, L. A., Solle, J. C., Dumanis, S. B., Riley, E. A. U., Periñán, M. T., Okubadejo, N. U., Klein, C., et al. (2025) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2025.07.014 · Cited by 12
A Genome‐Wide Linkage Screen in the Amish with Parkinson Disease Points to Chromosome 6
Cummings, A. C., Lee, S. L., McCauley, J. L., Jiang, L., Crunk, A. E., McFarland, L. L., Gallins, P. J., Fuzzell, D., Knebusch, C., Jackson, C. E., et al. (2011) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2011.00643.x · Cited by 12
“Glucosidase beta acid is also a confirmed risk factor in sporadic forms of PD (Aharon-Peretz et al., 2004; Lwin et al., 2004).”
BackgroundLiu, J., & Zhang, H. (2013) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32214 · Cited by 11
“Compared with previous studies [Aharon-Peretz et al., 2004; Lwin et al., 2004; Clark et al., 2005; Sato et al., 2005; Eblan et al., 2006; Toft et al., 2006; Ziegler et al., 2007; Mitsui et al., 2009; Sidransky et al., 2009; Hu et al., 2010; Mao et al., 2010; Nishioka et al., 2010; Lesage et al.,…”
BackgroundResultInfluentialA Lysosomal Lair for a Pathogenic Protein Pair
Dawson, T. M., & Dawson, V. L. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002808 · Cited by 13
Kumar, S., Yadav, N., Pandey, S., & Thelma, B. K. (2018) · Journal of Genetics · doi:10.1007/s12041-018-0953-5 · Cited by 11
Decreased Expression of Lysosomal Alpha-Galactosiase A Gene in Sporadic Parkinson’s Disease
Wu, G., Huang, J. A., Feng, X., Zhang, A., Li, J., Pang, S., Gu, K., Dong, H., Zhang, J., Gao, H., et al. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0516-0 · Cited by 11
The Link Between Lysosomal Storage Disorders and More Common Diseases
Beck, M. (2016) · Journal of Inborn Errors of Metabolism and Screening · doi:10.1177/2326409816682767 · Cited by 11
“2% (95 of 1543) of control participants carried a GBA mutation (92 were heterozygous for the mutation N370S and 3 were heterozygous for the mutation 84GG).(17) The suggestion that heterozygosity for a GBA mutation predisposes to Parkinson disease was confirmed in an international study in which 5691 patients with Park…”
BackgroundGBA mutations and Parkinson disease
Scholz, S. W., & Jeon, B. S. (2015) · Neurology · doi:10.1212/wnl.0000000000001321 · Cited by 11
Secretory autophagy mediates lysosomal and autophagic degradation for α-synuclein proteostasis
Sawai, T., Nakamura, Y., & Arawaka, S. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110474 · Cited by 11
“To test whether SNAP23 or STX4 KD causes lysosome damage independently of the blockade of autophagic secretion, we examined cells transfected with siRNAs against GBA , which encodes a lysosomal enzyme, β -glucocerebrosidase, and whose variants increase susceptibility to PD (22).”
Lipotoxicity Downstream of α-Synuclein Imbalance: A Relevant Pathomechanism in Synucleinopathies?
Tripathi, A., Fanning, S., & Dettmer, U. (2021) · Biomolecules · doi:10.3390/biom12010040 · Cited by 10
The Interplay Between Proteostasis Systems and Parkinson’s Disease
Lázaro, D. F., & Outeiro, T. F. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-38266-7_9 · Cited by 12
Clinical overview and phenomenology of movement disorders
Fahn, S., Jankovic, J. J., & Hallett, M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-2369-4.00001-9 · Cited by 16
Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease
Vieira, S. R. L., & Morris, H. R. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.679927 · Cited by 10
Genetics of Parkinson's Disease
Huang, Y. M., Chan, P., & Halliday, G. M. (2007) · Elsevier eBooks · doi:10.1016/b978-044452809-4/50169-1 · Cited by 12
SMPD1 mutations and Parkinson disease
Dagan, E., Adir, V., Schlesinger, I., Borochowitz, Z. U., Ayoub, M., Mory, A., Nassar, M., Kurolap, A., Aharon‐Peretz, J., & Gershoni‐Baruch, R. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.08.019 · Cited by 10
Self-citationStructural and dynamics insights into the GBA variants associated with Parkinson’s disease
Mahmood, A., Samad, A., Bano, S., Umair, M., Ajmal, A., Ilyas, I., Shah, A. A., Li, P., & Hu, J. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2233617 · Cited by 9
“Some GBA1 variants have been associated with PD that influence the phenotype of PD which led to the investigation of possible link of GBA enzyme with parkinsonism and PD (Aharon-Peretz et al., 2004; Tayebi et al., 2003).”
BackgroundiSCORE-PD: an isogenic stem cell collection to research Parkinson’s disease
Busquets, O., Li, H., Syed, K. M., Jerez, P. Á., Dunnack, J., Bu, R. L., Verma, Y., Pangilinan, G. R., Martin, A., Straub, J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74355-8 · Cited by 10
Autophagy Process in Parkinson’s Disease Depends on Mutations in the GBA1 and LRRK2 Genes
Bezrukova, A. I., Basharova, K. S., Emelyanov, A., Rybakov, A. V., Miliukhina, I. V., Пчелина, С. Н., & Usenko, T. S. (2025) · Biochemical Genetics · doi:10.1007/s10528-025-11125-z · Cited by 10
Arylsulphatase A activity in familial parkinsonism: a pathogenetic role?
Antelmi, E., Rizzo, G., Fabbri, M., Capellari, S., Scaglione, C. L. M., & Martinelli, P. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7425-5 · Cited by 9
Bastien, J., Menon, S., Messa, M., & Nyfeler, B. (2021) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2021.101018 · Cited by 10
Bridging Molecular Genetics and Biomarkers in Lewy Body and Related Disorders
Ho, G. J., Liang, W., Waragai, M., Sekiyama, K., Masliah, E., & Hashimoto, M. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/842475 · Cited by 10
“3.1.2. α-Synuclein Mutations in PD and DLB.”
InfluentialLRRK2, GBA and SMPD1 Founder Mutations and Parkinson's Disease in Ashkenazi Jews
Dagan, E., Schlesinger, I., Kurolap, A., Ayoub, M., Nassar, M., Aharon‐Peretz, J., & Gershoni‐Baruch, R. (2016) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000447450 · Cited by 9
Self-citationThe modifying effect of mutant LRRK2 on mutant GBA1 -associated Parkinson disease
Serebryany-Piavsky, V., Egulsky, L., Manoim-Wolkovitz, J. E., Anis, S., Hassin‐Baer, S., Parnas, M., & Mia, H. (2025) · Human Molecular Genetics · doi:10.1093/hmg/ddaf062 · Cited by 9
Ni, Y., Cai, H., Shao, Y., & Le, W.-D. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00931-7 · Cited by 9
“Notably, GD patients and their first-degree relatives show an increased risk of PD [23, 24], and large-scale studies confirm that heterozygous GBA1 mutations significantly increase PD susceptibility [6, 25].”
Shimo, H., Nakamura, M., Tomiyasu, A., Ichiba, M., Ueno, S., & Sano, A. (2010) · Neuroscience Research · doi:10.1016/j.neures.2010.12.001 · Cited by 9
Etiology and pathogenesis of Parkinson disease
Jankovic, J. J., Hallett, M., Okun, M. S., Comella, C., Fahn, S., & Goldman, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-31071-0.00005-6 · Cited by 9
Pesticides and Parkinson’s Disease
Arthur, G., & Jeff, M. (2011) · InTech eBooks · doi:10.5772/16479 · Cited by 8
Liao, X., Zhan, Z.-X., Luo, Y., Li, K., Wang, J., Guo, J., Yan, X., Xia, K., Tang, B., & Shen, L. H. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-196 · Cited by 8
“The glucocerebrosidase gene (GBA) serves as an example in PD: carriers of mutations in GBA causing Gaucher’s disease are at significantly increased risk for developing PD, with an earlier age of onset compared with PD patients who do not carry these mutations [11-13].”
BackgroundGlucocerebrosidase and parkinsonism: lessons to learn
Marković, I., Kresojević, N. D., & Kostić, V. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8085-4 · Cited by 9
Mechanisms Implicated in Parkinson Disease from Genetic Perspective
Popescu, C. (2016) · Medical & Clinical Reviews · doi:10.21767/2471-299x.1000028 · Cited by 8
A Therapeutic Target for Inhibition of Neurodegeneration: Autophagy
Pupyshev, A. B., Короленко, Т. А., & Tikhonova, M. A. (2017) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-017-0519-7 · Cited by 8
“In turn, Gaucher’s disease is not infrequently accompanied by signs of PD, particularly Lewy bodies with α-synuclein and loss of dopaminergic neurons [Aharon-Peretz et al., 2004].”
Principles of Protein Misfolding
Ramírez-Alvarado, M. (2008) · Progress in molecular biology and translational science · doi:10.1016/s0079-6603(08)00404-2 · Cited by 11
Zhang, L., Okada, T., Badawy, S. M. M., Hirai, C., Kajimoto, T., & Nakamura, S. (2018) · Scientific Reports · doi:10.1038/srep46964 · Cited by 8
Two lysosomal genes ATP13A2 and GBA1 interact to drive neurodegeneration
Gu, M., Zhao, J., Deng, M., Lin, G., Pan, X., Lin, W. W., Ma, M., Kim, J., Byeon, S. K., Pandey, A., et al. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00923-z · Cited by 7
Zhang, J., Wang, C., Li, Y., Xiao, Z., Cai, Z., Qian, Y., Shi, L., & Zhang, Q. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103159 · Cited by 7
Sawangareetrakul, P., Ngiwsara, L., Champattanachai, V., Chokchaichamnankit, D., Saharat, K., Cairns, J. R. K., Srisomsap, C., Khwanraj, K., Dharmasaroja, P., Pulkes, T., et al. (2021) · Biomedical Reports · doi:10.3892/br.2021.1412 · Cited by 7
Messelodi, D., Strocchi, S., Bertuccio, S. N., Baden, P., Indio, V., Giorgi, F. M., Taddia, A., Serravalle, S., Valente, S., Fonzo, A. D., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04813-2 · Cited by 7
“To further complicate the situation, some evidences prove the role of GBA1 mutations as a major genetic risk factor for the development of Parkinson ’ s disease 13 .”
Parkinson’s Disease: Basic Pathomechanisms and a Clinical Overview
Noyce, A. J., & Bandopadhyay, R. (2017) · Advances in neurobiology · doi:10.1007/978-3-319-57193-5_3 · Cited by 7
Sun, A., Chang, I. J., Lam, C. T., & Berry, G. T. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-812535-9.00014-5 · Cited by 11
Parkinson's disease: aetiology, diagnosis, and management.
Leung, H., & Mok, V. (2005) · PubMed · Cited by 7
Type I Gaucher Disease Following Chemotherapy for Light Chain Multiple Myeloma
Cheung, W. Y., Greenberg, C. R., Bernstein, K. N., Schacter, B., Fourie, T., & Seftel, M. D. (2007) · Internal Medicine · doi:10.2169/internalmedicine.46.6243 · Cited by 7
“Mutations such as chromosomal translocations between the GD locus and the light chain loci, which reside on different chromosomes, is a possible explanation but warrants further study (17, 20, 21).”
BackgroundGenetic Models of Parkinson’s Disease
Kachidian, P., & Gubellini, P. (2020) · Neuromethods · doi:10.1007/978-1-0716-0912-5_3 · Cited by 7
Free‐Water Imaging of the Substantia Nigra in GBA Pathogenic Variant Carriers
Zhang, D., Shi, Y., Yao, J., Zhou, L., Wei, H., Liu, J., Tong, Q., Ma, L., He, H., & Wu, T. (2023) · Movement Disorders · doi:10.1002/mds.29356 · Cited by 6
Alecu, J. E., Sigutova, V., Brazdis, R.-M., Lörentz, S., Bogiongko, M., Nursaitova, A., Regensburger, M., Roybon, L., Galler, K. M., Wrasidlo, W., et al. (2025) · BMC Neuroscience · doi:10.1186/s12868-025-00926-y · Cited by 6
Gaucher's Disease in Albanian Children: Casuistics and Treatment.
Shehi, B., Boçari, G., Vyshka, G., Xhepa, R., & Alushani, D. (2011) · PubMed · Cited by 6
Nakata, K., Takeda, S., Tanaka, A., Kwang, J., & Komano, J. A. (2017) · Journal of General Virology · doi:10.1099/jgv.0.000723 · Cited by 6
Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy
Walton, S., Fenyi, A., Tittle, T., Sidransky, E., Pal, G. D., Choi, S. G., Melki, R., Killinger, B. A., & Kordower, J. H. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00679-1 · Cited by 6
The Use of Biomarkers for Prediction and Prevention of Alzheimer’s and Parkinson’s Diseases
Mandel, S. A., & Korczyn, A. D. (2012) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-94-007-5866-7_6 · Cited by 7
“These mutations are most common among the Ashkenazi-Jewish population [159, 160].”
BackgroundWALKER, R. E. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)84059-0 · Cited by 6
Ribner, A., Altarescu, G., Zimran, A., & Elstein, D. (2011) · Movement Disorders · doi:10.1002/mds.23595 · Cited by 6
Clinical overview and phenomenology of movement disorders
Jankovic, J. J., Hallett, M., Okun, M. S., Comella, C., Fahn, S., & Goldman, J. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-31071-0.00001-9 · Cited by 7
A Study of the Calcium Complex of a Glucosylceramide, Soya-cerebroside II
Kurosu, M., Katayama, S., Shibuya, H., & Kitagawa, I. (2007) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.55.1758 · Cited by 6
Manifestaciones neurológicas en pacientes con enfermedad de Gaucher y en sus familiares
Giraldo, P., Capablo, J. L., Alfonso, P., Latre, P., García, B., & Pocoví, M. (2008) · Medicina Clínica · doi:10.1157/13124962 · Cited by 6
Rossini, L., & Rossini, P. (2006) · Cited by 6
Udayar, V., Gilormini, P., Bryois, J., Gehrlein, A., Chen, X., Sonea, S., Zhu, S., Deen, M. C., Anastasi, N., Murphy, A. E., et al. (2025) · ACS Central Science · doi:10.1021/acscentsci.5c00240 · Cited by 5
Usenko, T. S., Basharova, K. S., Bezrukova, A. I., Grigor’eva, E. V., Pavlova, S. V., Baydakova, G., Nikolaev, M. A., Николаевич, Г. И., Khegay, O. V., Miliukhina, I. V., et al. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70214 · Cited by 8
“…in the GBA1 gene (p.N370S or p.N409S according to the new nomenclature; p.L444P or p.L483P according to the new nomenclature) and the LRRK2 gene (p.G2019S) using allele-specific PCR or PCR followed by restriction analysis, as previously described (Aharon-Peretz et al. 2004; Emelyanov et al. 2018).”
Genetic analysis of the glucocerebrosidase gene in South Indian patients with Parkinson's disease
Kumar, A., Yadav, R., Kapoor, S., Madhukar, M., Naduthota, R., & Pal, P. (2018) · Neurology India · doi:10.4103/0028-3886.246249 · Cited by 5
Xu, D., Li, G., Wu, Z., Liu, X., Yang, X., & Wang, J. (2021) · Neuroreport · doi:10.1097/wnr.0000000000001685 · Cited by 5
Características clínicas de las formas neurológicas de la enfermedad de Gaucher
Liesa, J. L. C., de Cabezón, A. S., Alejos, R. A., & Ara, J. R. (2011) · Medicina Clínica · doi:10.1016/s0025-7753(11)70010-0 · Cited by 5
Genetics of Parkinson’s Disease
Hernandez, D. G., & Singleton, A. (2015) · Springer eBooks · doi:10.1007/978-3-319-17223-1_2 · Cited by 5
Genomic Medicine and Neurology
Vance, J. M., & Tekin, D. (2011) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000396960.90316.8e · Cited by 5
“studies have now shown that carriers for Gaucher disease in the Ashkenazi Jewish population have a fivefold or greater risk for developing Parkinson disease.(4) The frequency of Gaucher carriers in the Ashkenazi population is about 12%.”
BackgroundPET Molecular Imaging in Familial Parkinson's Disease
Matarazzo, M., Wile, D. J., Mackenzie, M., & Stoessl, A. J. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.09.003 · Cited by 5
Current concepts on the etiology and pathogenesis of Parkinson disease
Fahn, S., Jankovic, J. J., & Hallett, M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-2369-4.00005-6 · Cited by 7
Adaptive Immunity and Parkinson's Disease
Elyaman, W. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041639 · Cited by 5
Emerging parkinsonian phenotypes
Elia, A. E., & Albanese, A. (2010) · Revue Neurologique · doi:10.1016/j.neurol.2010.07.017 · Cited by 6
Étude rétrospective sur dix ans des patients atteints de maladie de Gaucher au CHU de Rennes
Revest, M., Perlat, A., Decaux, O., Lamy, T., Vérin, M., Brissot, P., & Grosbois, B. (2009) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2009.03.357 · Cited by 4
Diagnostic moléculaire de la maladie de Gaucher en Tunisie
Cherif, W., Turkia, H. B., Rhouma, F. B., Riahi, I., Chemli, J., Amaral, O., Sá-Miranda, C., Caillaud, C., Kaabachi, N., Tebib, N., et al. (2012) · Pathologie Biologie · doi:10.1016/j.patbio.2012.03.006 · Cited by 4
Rethinking fatigue in Gaucher disease
Zion, Y. C., Pappadopulos, E. A., Wajnrajch, M. P., Sandberg, D. E., & Rosenbaum, H. (2014) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2013.12.055 · Cited by 4
“Pulmonary hypertension, cholelithiasis, and autoimmune phenomena may occur in Gaucher patients and the mutations for Type 1 GD might predispose carriers and patients with GD to Parkinson disease [2, 6, 7].”
Self-citationGaucher disease and Lupus: A rare association?
Jerónimo, T. M., Cabrita, A., Pimentel, A., Vidinha, J., Fragoso, A., Santos, V., Bernardo, I., Viana, H., Carvalho, F., Brito, H., et al. (2016) · Nefrología · doi:10.1016/j.nefro.2016.05.014 · Cited by 4
Kovalenko, V., Александровна, Х. Е., Рзаев, Д. А., & Medvedev, S. P. (2017) · Genes and Cells · doi:10.23868/201707012 · Cited by 4
Genetic Risk Factors and Lysosomal Function in Parkinson Disease
Montenegro, M. V. B., Amaral, C. E. D. M., & da Silva, L. C. S. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.91850 · Cited by 4
Rare Diseases in Glycosphingolipid Metabolism
Zhou, H., Wu, Z., Wang, Y., Wu, Q., Hu, M., Ma, S., Zhou, M., Sun, Y., Yu, B., Ye, J., et al. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-0394-6_13 · Cited by 4
Early-onset parkinsonism and hereditary spastic paraplegia type 7: pearls and pitfalls
Phillips, O. W., Amato, A. M., & Fernandez, H. H. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105315 · Cited by 4
Chapter 8 α-Synuclein and Synucleinopathies
Schlossmacher, M. G. (2007) · Blue books of neurology · doi:10.1016/s1877-184x(09)70059-0 · Cited by 9
Delta deletion 4977 in mitochondrial DNA in patients with idiopathic Parkinson’s disease
Taravari, A., Панов, С., Petrov, I., Petrova, V., Medziti, F., & Haliti, G. (2014) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2014_002 · Cited by 4
“are not biologically signifi cant (2, 6, 9, 11, 32).”
Dinur, T., Becker‐Cohen, M., Revel‐Vilk, S., Zimran, A., & Arkadir, D. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202422 · Cited by 4
“Pathogenic variants in the Glucocerebrosidase ( GBA ) gene are associated with Parkinson’s disease (PD) [1–3].”
Fitzmaurice, A. G. (2012) · CaltechTHESIS (California Institute of Technology) · doi:10.7907/fdag-hh02 · Cited by 16
Treating patients with Gaucher disease and parkinsonism: Misrepresentation in a title
Göker-Alpan, Ö., & Sidransky, E. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.01.002 · Cited by 4
Lane-Donovan, C., Paredes, M., & Kao, A. W. (2025) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2025.102854 · Cited by 3
Shimizu, T., Isik, S., Kamath, N., & Yue, Z. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00555-3 · Cited by 4
“Mutations in GBA1 were first identified as risk factors for PD in Ashkenazi Jewish populations and subsequently validated in a larger multicenter study [144, 145].”
Actinomyces viscosus promotes neuroprotection in C. elegans models of Parkinson’s disease
Ngana, G. S., Bernardo, M. A. D., Surette, M. G., & MacNeil, L. T. (2025) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2025.112061 · Cited by 4
Fruscio, G. D., Banfi, S., Nigro, V., & Ballabio, A. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6934-0_15 · Cited by 3
Экзосомы плазмы крови при наследственных формах болезни Паркинсона
Kulabukhova, D. G., Garaeva, L. A., Емельянов, А. К., Senkevich, K. A., Gracheva, E., Miliukhina, I. V., Варфоломеева, Е. Ю., Тимофеева, А. А., Shvartsman, A., Shtam, T. A., et al. (2021) · Molecular Biology · doi:10.31857/s0026898421010092 · Cited by 6
Plasma Exosomes in Inherited Forms of Parkinson’s Disease
Kulabukhova, D. G., Garaeva, L. A., Emelyanov, A., Senkevich, K. A., Gracheva, E., Miliukhina, I. V., Varfolomeeva, E. Y., Timofeeva, A., Шварцман, А. Л., Shtam, T. A., et al. (2021) · Molecular Biology · doi:10.1134/s002689332101009x · Cited by 4
Clinical and Diagnostic Findings of 19 Gaucher Patients in Albania
Velmishi, V. (2013) · Journal of Liver · doi:10.4172/2167-0889.1000122 · Cited by 3
“Only 30% of individuals with this type of the disease will represent clinical symptoms [7-12].”
BackgroundGankina, O. A., Васенина, Е. Е., Levin, O. S., Fedotova, E. Y., & Illarioshkin, S. N. (2016) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20161166271-76 · Cited by 4
Genetics of Parkinson's Disease—An Overview
Klein, C. (2009) · Blue books of neurology · doi:10.1016/b978-1-4160-6641-5.00002-7 · Cited by 3
Lysosomal enzyme defects and Parkinson disease
Sharma, N. (2013) · Neurology · doi:10.1212/wnl.0b013e31828f1958 · Cited by 3
“In the 1960s, the loss of dopamine neurons in the substantia nigra was linked to the etiology of PD.1 This finding paved the way for the development of dopaminergic therapy to alleviate some of the symptoms of PD.”
BackgroundDisease-specific interventions: The use of cell and gene therapies for Parkinson disease
Barker, R. A., & Buttery, P. C. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-90120-8.00003-4 · Cited by 3
Zuckerman, S., Zimran, A., Szer, J., Revel‐Vilk, S., & Altarescu, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26030912 · Cited by 2
“In the last few decades, an association between GD and Parkinson’s disease (PD), a neurodegenerative condition which generally becomes clinically manifest in the later years of life, has been identified [7].”
Bases moléculaires de la maladie de Parkinson
Lesage, S., & Brice, A. (2010) · Encyclopédie médico-chirurgicale. Neurologie · doi:10.1016/s0246-0378(10)51090-x · Cited by 2
Lipid Metabolism in Neurodegenerative Diseases
Lim, L., Shui, G., & Wenk, M. R. (2012) · Wiley eBooks · doi:10.1002/9783527655946.ch14 · Cited by 2
Introduction to α‐Synucleinopathies
Spillantini, M. G. (2011) · Wiley eBooks · doi:10.1002/9781444341256.ch20 · Cited by 3
Metadata
- Authors
- Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- ORCID
- Rosenbaum, Hanna
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-04
- Volume
- 351
- Issue
- 19
- Pages
- 1972-1977
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992253341
- Cited by
- 597
- References
- 32
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 17 · 2023: 21 · 2022: 32 · 2021: 27 · 2020: 16 · 2019: 25 · 2018: 26 · 2017: 32 · 2016: 35 · 2015: 29 · 2014: 28 · 2013: 39 · 2012: 28
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase gene, GBA mutations, Ashkenazi Jews, N370S mutation, Alzheimer's disease, parkinsonism, genetic screening, heterozygosity, genotype-phenotype correlation, gene-environment interaction
- MeSH terms
- Alzheimer Disease, DNA Mutational Analysis, Female, Glucosylceramidase, Heterozygote, Humans, Jews, Male, Mutation, Parkinson Disease, Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.